Company Overview
Snapshot
Founded in January 2022 by Shaul Ozeri, NovaPulse operates with 1–10 employees. The company has secured funding across one round from Almeda Ventures and MEDX Xelerator. In September 2022, NovaPulse received investment from Almeda Ventures and MEDX Xelerator.
Business overview
NovaPulse is a bioconvergence company focused on addressing peripheral artery disease (PAD), specifically targeting claudication patients who experience pain and difficulty walking due to insufficient blood supply to their legs. The company develops medical devices and therapeutics within the Health Tech & Life Sciences sector, with a focus on cardiology and heart diseases. NovaPulse's core technology involves implants and it serves the healthcare market, particularly providers.
Strategic signal
In September 2022, NovaPulse, a vascular medtech startup, secured investment from Almeda Ventures and MEDX Xelerator. This funding, announced shortly after the company's founding, signals strong early-stage validation for NovaPulse's bioconvergence approach to the multi-billion dollar peripheral artery disease market, suggesting investor confidence in its potential to address a significant unmet medical need.
Log in to access full profile ›Company Intelligence Q&A
- When was NovaPulse founded?
- NovaPulse was founded in January 2022.
- Who founded NovaPulse?
- NovaPulse was founded by Shaul Ozeri.
- What is NovaPulse's primary focus?
- NovaPulse specializes in treating peripheral artery disease, focusing on patients suffering from claudication due to insufficient blood supply to their legs.
- Which investors participated in NovaPulse's funding round in September 2022?
- In September 2022, NovaPulse received investment from Almeda Ventures and MEDX Xelerator.
- What is the current product stage of NovaPulse's offerings?
- NovaPulse's product is currently in the clinical trial stage, indicating it is undergoing testing in human subjects to evaluate its safety and efficacy before potential regulatory approval and market release.